SuperworthIllumina ILMN
- Market cap
- $40.7B
- PE
- 50.1×
- 10y median 51.4×
- Forward PE
- 47.2×
- 10y median 56.2×
- Price to sales
- 9.1×
- EV/EBIT
- 47.7×
- Revenue, 12 months
- $4.5B
- +5% on a year ago
- Net margin
- 18.4%
- Free cash flow yield
- 2.3%
Illumina trades at 50.1× trailing earnings, near its ten-year median. Revenue was $4.5B over the last twelve months, up 5% on a year earlier with a 18% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1B+0% | $1.1B+4% | $1.1B−1% | $1.1B−5% | $1.1B−4% | $1.1B−2% | $1B−3% | $1.1B−5% | $1.1B+0% | $1.2B+5% | $1.1B+5% | $1.2B+9% | |
| Cost of revenue | $435M+9% | $448M+9% | $409M−5% | $391M−12% | $335M−23% | $376M−16% | $358M−13% | $364M−7% | $351M+5% | $400M+6% | $370M+3% | $389M+7% |
| Gross profit | $684M−5% | $674M+0% | $667M+2% | $721M−2% | $745M+9% | $728M+8% | $683M+2% | $695M−4% | $733M−2% | $759M+4% | $721M+6% | $770M+11% |
| R&D | $315M−3% | $341M−1% | $339M−1% | $325M−9% | $253M−20% | $256M−25% | $252M−26% | $247M−24% | $229M−10% | $239M−7% | $240M−5% | $252M+2% |
| SG&A | $303M+108% | $485M+12% | $439M+16% | $147M−68% | $239M−21% | $279M−43% | $267M−39% | $234M+59% | $277M+16% | $309M+11% | $272M+2% | $273M+17% |
| −$754M−79% | −$164M+29% | −$111M+73% | −$1.6B+1760% | $741M | $175M | $164M | $214M | $227M−69% | $201M+15% | $209M+27% | $245M+15% | |
| Interest expense | $19M+217% | $18M+100% | $18M−10% | $20M+5% | $36M+90% | $25M+39% | $25M+39% | $25M+25% | $25M−31% | $26M+4% | $24M−4% | $24M−4% |
| Pre-tax income | −$782M−79% | −$167M−1% | −$109M+40% | −$2B+2120% | $720M | $187M | $182M | $306M | $220M−69% | $377M+102% | $157M−14% | $260M−15% |
| −$28M | $8M | $17M | $12M−92% | $15M | $0 | $51M+200% | $71M+492% | $70M+367% | $43M | $23M−55% | $53M−25% | |
| Net income | −$754M−80% | −$175M+26% | −$126M | −$2B+750% | $705M | $187M | $131M | $235M | $150M−79% | $334M+79% | $134M+2% | $207M−12% |
| −$4.77−80% | −$1.11+25% | −$0.79 | −$12.48+743% | $4.42 | $1.18 | $0.82 | $1.49 | $0.98−78% | $2.18+85% | $0.87+6% | $1.35−9% | |
| 158M+1% | 158M+1% | 159M+1% | 159M+1% | 160M+1% | 159M+1% | 159M+0% | 157M−1% | 154M−4% | 153M−4% | 154M−3% | 153M−3% |
EPS, diluted: 8 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22 and Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.2B | $1.1B to $1.2B | $1.36 | $1.35 to $1.37 | 12 |
| Q4 FY26 | $1.2B | $1.2B to $1.2B | $1.54 | $1.42 to $1.58 | 11 |
| Q1 FY27 | $1.2B | $1.1B to $1.2B | $1.33 | $1.27 to $1.34 | 4 |
| Q2 FY27 | $1.2B | $1.2B to $1.2B | $1.49 | $1.42 to $1.50 | 4 |
| Q3 FY27 | $1.2B | $1.2B to $1.2B | $1.57 | $1.50 to $1.58 | 5 |
| Q4 FY27 | $1.3B | $1.2B to $1.3B | $1.71 | $1.63 to $1.72 | 8 |
| Q1 FY28 | $1.2B | $1.2B to $1.3B | $1.50 | $1.44 to $1.52 | 5 |
| Q2 FY28 | $1.3B | $1.3B to $1.3B | $1.78 | $1.70 to $1.80 | 5 |
Peers
Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| DHRDanaher | $162B | 40.9× | 34.2× | 25.4× | 6.5× | +5% | 15.9% |
| Peer median | $38.8B | 38.4× | 34.3× | 26.4× | 6.5× | +8% | 12.6% |
Investors who own it
Investors we follow who held Illumina at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management1.2% of portfoliotrimmed
- Baillie GiffordBaillie Gifford0.2% of portfoliotrimmed
- Ron BaronBaron Capital0.1% of portfolioadded
More on Illumina
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 15Diagnostics and research stocks cheapest against their own PE history
- #6of 39Diagnostics and research stocks with the highest profit margins
- #7of 11Diagnostics and research stocks with the fastest expected revenue growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .